What the trial was testing
The ADVOR enrolled 519 patients with heart failure. The study was sponsored by Ziekenhuis Oost-Limburg and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was long-term safety (phase 4). Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
42% of patients on acetazolamide successfully removed excess fluid within three days, compared to 31% on standard treatment.
The New England journal of medicine · 2022 · NCT03505788
These findings — that nearly half of patients on acetazolamide cleared excess fluid within three days versus about one-third on standard treatment — were published in the The New England journal of medicine and represent the headline result of the study.
Researchers tracked outcomes across 519 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with heart failure, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
Acetazolamide is FDA-approved but not yet standard practice for heart failure fluid overload. This large Phase 4 trial showed it helps remove fluid faster when added to standard diuretics during hospitalization. If you're hospitalized for heart failure with fluid buildup, ask your doctor if adding acetazolamide might help.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open heart failure trials
Sacubitril/Valsartan in Patients With Prosthetic Heart Valves With Heart Failure and Reduced Ejection Fraction
This study aims to evaluate the effect of sacubitril/valsartan in patients with prosthetic heart valves with heart failure with reduced ejection fraction (HFrEF).
Lifestyle Behaviours of Women Newly Diagnosed With Heart Failure
Heart Failure occurs when the heart's ability to pump blood is reduced. Heart failure can lead to symptoms of breathlessness, fatigue and ankle swelling, and result in health complications including damage to other organs (e.g. kidneys), reduced function and quality of life. Although the symptoms of heart failure are similar for men and women, there are sex differences. Lifestyle behaviours such as physical activity are important modifiable risk factor for heart failure. Women continue to be underrepresented in heart failure studies and treatment guidelines are male-derived due to these disparities in recruitment. The purpose of the present study is to evaluate the physical activity levels, sedentary behaviour, sleep and quality of life and understand the barriers and facilitators to these lifestyle behaviours in women newly diagnosed with heart failure.